Cadence Pharmaceuticals, Inc.

NASDAQ: CADX
Cadence Pharmaceuticals agreed Tuesday to be bought out by Mallinckrodt for $1.3 billion, or a more than 27% premium to Monday's closing share price. Some investors may anticipate a sweetened offer.
Charley Blaine
Source: ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already...
Lee Jackson
Shares only briefly broke above last week’s close today, as decliners outnumber gainers by about 4 to 1 in the late afternoon. Tech stocks held up fairly well early as news of Warren Buffet’s buy...
Paul Ausick
Many investors track the largest increase in short selling, but there is another crucial way to look at short interest: the days to cover often tells just how actively shorted a stock is, as does a...
Jon C. Ogg
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has trumped Valeant Pharmaceuticals International, Inc. (NYSE: VRX) after it agreed to acquire Cephalon Inc. (NASDAQ: CEPH) in a $6.8 billion...
Jon C. Ogg
Active traders and day traders have many stocks to choose from this Wednesday morning.  We are tracking news and moves in shares of BP plc (NYSE: BP), Cadence Pharmaceuticals Inc. (NASDAQ: CADX),...
Jon C. Ogg
Today’s version of the BioHealth Business Daily is again full of stocks on the move with news, and some not on news.  Array BioPharma, Inc. (NASDAQ: ARRY), BioDelivery Services International Inc....
Jon C. Ogg
Today’s version of the BioHealth Business Daily has many stocks moving on news, but oddly many of the real news stocks are hardly moving and were eliminated from today’s report.  Today’s...
Jon C. Ogg
These are the top ten analyst upgrades, downgrades, and initiations we have seen from Wall Street research calls early this Monday: Cadence Pharmaceuticals (NASDAQ: CADX) Cut to Perform at...
Douglas A. McIntyre
These are this morning’s top day trader and active trader alert stocks.  More detailed analysis and data has been offered via a link to each story at VSInvestor.com: Abercrombie & Fitch...
Douglas A. McIntyre
These are this morning’s top day trader and active trader alerts seen in the pre-market trading hours.  We also included some options color from yesterday.  A link has been provided for more...
Douglas A. McIntyre
Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for...
Douglas A. McIntyre
Shares in Cadence Pharmaceuticals (CADX) are off as much as 50% on news that one of its drugs had failed in trials. According to Reuters "the biopharmaceutical company said one trial did not...
Douglas A. McIntyre